Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Impact of an Oncology Clinical Pharmacist on Patient Engagement in Self-Administered Oral Oncolytic Therapy: Case Study of Venetoclax in Acute Myeloid Leukemia Patients

Version 1 : Received: 24 June 2021 / Approved: 28 June 2021 / Online: 28 June 2021 (15:32:14 CEST)

How to cite: Palmer, S.; Chen, A.; Dennison, T.; Czech, C.; Auten, J.; Buhlinger, K.; Muluneh, B. Impact of an Oncology Clinical Pharmacist on Patient Engagement in Self-Administered Oral Oncolytic Therapy: Case Study of Venetoclax in Acute Myeloid Leukemia Patients. Preprints 2021, 2021060680 (doi: 10.20944/preprints202106.0680.v1). Palmer, S.; Chen, A.; Dennison, T.; Czech, C.; Auten, J.; Buhlinger, K.; Muluneh, B. Impact of an Oncology Clinical Pharmacist on Patient Engagement in Self-Administered Oral Oncolytic Therapy: Case Study of Venetoclax in Acute Myeloid Leukemia Patients. Preprints 2021, 2021060680 (doi: 10.20944/preprints202106.0680.v1).

Abstract

Oncology clinical pharmacists are uniquely positioned to make interventions to increase patient activation and engagement. To accomplish this goal, pharmacists can target health system-related, provider-related, and patient-related factors to help enhance patient-centered care and drive behavioral health changes. Interventions that pharmacists must tackle include educating team members and patients on the medication acquisition process, communicating urgency of treatment, optimizing workflows, facilitating guideline recommendations, preventing, and managing treatment toxicities, and promoting patient self-advocacy through education and shared decision-making. As crucial members of the healthcare team, oncology clinical pharmacists can simplify highly complex treatment regimens to facilitate and optimize patients’ ownership of their care. This review will focus on the example of venetoclax treatment in acute myeloid leukemia to demonstrate the impact that pharmacists provide that leads to behavioral change of patients and clinicians.

Subject Areas

patient activation; patient engagement, behavioral health change; self-administered therapy, oral oncolytic

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.